



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



AT-130

Item No. 35453

CAS Registry No.: 211364-06-6
Formal Name: N-[(1E)-2-bromo-2-(2-methoxyphenyl)-1-(1-piperidinylcarbonyl)ethenyl]-4-nitro-benzamide
MF: C₂₂H₂₂BrN₃O₅
FW: 488.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

AT-130 is supplied as a solid. A stock solution may be made by dissolving the AT-130 in the solvent of choice, which should be purged with an inert gas. AT-130 is soluble in the organic solvent DMSO (sonicated) at a concentration of approximately 25 mg/ml. AT-130 is also soluble in ethanol.

Description

AT-130 is an antiviral agent.^{1,2} It is a non-nucleoside inhibitor of hepatitis B virus (HBV) replication in wild-type and rtL180M, rtM204I, and rtL180M + rtL204V lamivudine-resistant strains of HBV (IC₅₀s = 2.4, 1.6, 5.1, and 1.3 μM, respectively).² AT-130 inhibits viral DNA synthesis in HBV-infected HepAD38 cells (EC₅₀ = 0.13 μM) and reduces the amount of encapsidated RNA in HBV-infected HepG2 cells.^{2,3}

References

1. Perni, R.B., Conway, S.C., Ladner, S.K., *et al.* Phenylpropenamide derivatives as inhibitors of hepatitis B virus replication. *Bioorg. Med. Chem. Lett.* **10**(23), 2687-2690 (2000).
2. Delaney, W.E., IV, Edwards, R., Colledge, D., *et al.* Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. *Antimicrob. Agents Chemother.* **46**(9), 3057-3060 (2002).
3. Feld, J.J., Colledge, D., Sozzi, V., *et al.* The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. *Antiviral Res.* **76**(2), 168-177 (2007).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/12/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM